Illimis Logo (WIPO, 17.03.2022)
WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke Illimis wurde als Bildmarke am 17.03.2022 bei der Weltorganisation für geistiges Eigentum angemeldet.
Logodesign (Wiener Klassifikation)
#Briefe, die eine besondere Form des Schreibens darstellen
| Markenform | Bildmarke |
| Aktenzeichen | 1665605 |
| Länder | 
|
| Basismarke |
Nr. ,
04. August 2024
|
| Anmeldedatum | 17. März 2022 |
| Ablaufdatum | 17. März 2032 |
Markeninhaber
2nd, 3rd Fl, 18, Heolleung-ro 569-gil,
Gangnam-gu
KR
Gangnam-gu
KR
Markenvertreter
A-302, USPACE2,
Daewangpangyo-ro 670, Bundang-gu,
KR
Waren und Dienstleistungen
05
Pharmaceutical preparations for the treatment of auto-immune
diseases; pharmaceutical agents affecting sensory organs;
pharmaceutical agents affecting peripheral nervous system;
pharmaceutical preparations for activating cellular
function; pharmaceutical preparations acting on the central
nervous system; pharmaceutical preparations for respiratory
organs; pharmaceutical preparations for the prevention of
disorders of the nervous system; pharmaceutical preparations
for the treatment of cardiovascular disease;
pharmaceuticals; pharmaceutical preparations for the
treatment of inflammatory diseases; ophthalmic preparations;
pharmaceutical preparations for the treatment of eye
diseases and conditions; pharmaceutical preparations for the
treatment of degenerative brain disease; pharmaceutical
preparations for the treatment of brain dysfunction;
pharmaceutical preparations for the treatment of stroke;
pharmaceutical preparations for the treatment of
cerebrovascular disease; pharmaceutical preparations for the
treatment of dementia; pharmaceutical preparations for the
treatment of Alzheimer's disease; pharmaceutical
preparations for use in the treatment of solid tumors and
growths, hemolytic diseases and disorders, amyloidosis,
metabolic diseases and disorders, lupus, and inflammation
and autoimmune diseases and disorders
42
Pharmaceutical products development; research and
development in the field of age-related diseases/disorders
and degenerative diseases; research and development in the
field of chronic malady/disease and dysfunction; scientific
research in the field of gene therapy; medical scientific
research in the field of brain disease; medical scientific
research in the field of neurological diseases; research in
biotechnology and antibody fields; biological research;
scientific research in the field of cancer disease;
monitoring and inspection for quality control and analysis
of active substances in the pharmaceutical research field;
research for quality inspection related to human hygiene
management for medical research purposes; research of
autoimmune disease; development of cell therapy; stem cell
collection for medical research; cell processing and culture
for medical research; research and development in the field
of inflammatory disease; research and development in the
field of eye disease; research and development in the field
of amyloidosis; consultancy and information services
relating to pharmaceutical quality control
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 08. Mai 2023 | 2023/19 Gaz | CH | Ablehnung |
| 27. Februar 2023 | 2023/9 Gaz | US | Ablehnung |
| 22. Dezember 2022 | 2023/4 Gaz | KR | RAW: Partial Ceasing Effect |
| 03. November 2022 | 2022/44 Gaz | EM | Ablehnung |
| 30. September 2022 | 2022/41 Gaz | RAW: Limitation | |
| 23. September 2022 | 2022/39 Gaz | CN | Ablehnung |
| 08. September 2022 | 2022/36 Gaz | GB | Ablehnung |
| 17. März 2022 | 2022/21 Gaz | KR | Eintragung |
ID: 141665605